Clinical trials
PET clinical trials
Below are recruiting pet clinical trials, each written for real people, not researchers. We’re tracking 590 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT05008146RecruitingEarly Phase 1
Brain imaging study for cocaine use disorder interactions
This early-phase study uses brain imaging to understand how cocaine use disorder affects brain function. It may help researchers learn more about brain pathways involved in craving and treatment targets.
Pittsburgh, PennsylvaniaAges 18–55 - NCT07179770RecruitingPhase 1
Belzutifan and imaging in advanced kidney cancer
This trial tests a new drug called belzutifan combined with a special imaging agent (89Zr-DFO-girentuximab) to see how they affect PET scans in people with advanced clear cell kidney cancer. It may help doctors better understand the cancer and guide treatment.
New York, New YorkAges 18 years+ - NCT06549465RecruitingPhase 2
Ac-225 rosopatamab for PSMA-positive castration-resistant prostate cancer
This trial tests a radioactive drug (Ac-225 rosopatamab tetraxetan) that targets a protein called PSMA on prostate cancer cells. It is for patients whose cancer has stopped responding to hormone therapy and has spread to other parts of the body.
San Diego, CaliforniaAges 18 years+ - NCT06089486Recruiting
New Heart Scan for Transplant Patients
This study investigates a new heart scan (called a cardiac PET) to detect early signs of blood vessel disease in heart transplant patients. If you had your transplant 2 to 10 years ago, this scan might be an alternative to the usual yearly checkup with an invasive procedure (angiogram).
Calgary, AlbertaAges 18 years+ - NCT07586215Recruiting
HER2-targeted PET imaging to predict treatment response in advanced breast cancer
This trial tests whether a special type of PET scan can predict how well a targeted cancer drug (T-DXd) will work for patients with advanced breast cancer that has specific HER2 markers. The goal is to help doctors personalize treatment decisions based on imaging results.
ShanghaiAges 18 years+ - NCT06644716Recruiting
FAPI PET-CT scan to find unknown primary cancer
This study tests a new type of PET-CT scan using a tracer called FAPI to find the original source of cancer when standard tests have not been able to. It may help identify the primary tumor in people with cancer that has spread from an unknown location.
AmsterdamAges 18–99 - NCT03514524Enrolling by invitation
PET-MRI brain scans for recent injury, stroke, or mild memory changes
This study uses special brain scans to measure proteins and connections in the brain after a recent injury, stroke, or in people with mild memory/behavior changes. The goal is to understand brain changes and how they relate to symptoms, which may help future diagnosis and treatment.
LeuvenAges 18–80 - NCT07162779Enrolling by invitation
New PET scan for advanced prostate cancer patients
This trial tests a new type of PET scan using a radioactive tracer called [68Ga]DOTA-IR-780-C-4 to see if it can find prostate cancer cells that express a protein called PSMA. If you have advanced prostate cancer that has stopped responding to standard treatments, this scan may help your doctor better understand your cancer and possibly guide future care.
Wuxi, JiangsuAges 18–80 - NCT05796102Recruiting
Testing an MRI-PET scan for esophagus cancer planning
This study tests whether a combined PET-MRI scan can be done safely and used to help plan treatment for people with locally advanced esophageal cancer. It may improve how doctors map the cancer and plan radiation therapy, but it is mainly a feasibility (testing-setup) study.
Toronto, OntarioAges 18 years+ - NCT06867588Recruiting
Adding PSMA PET to MRI for prostate cancer detection
This study is testing whether a special scan called a PSMA PET can help find significant prostate cancer in men who are already scheduled for an MRI-guided biopsy. It aims to see if combining the two scans gives a better picture of which prostate areas need to be biopsied.
BrusselsAges 18 years+ - NCT06534190RecruitingPhase 2
PET scan to guide immunotherapy in advanced solid tumors
This trial uses a special PET scan to see how immune cells (CD8 T cells) are working in your tumor before you start a PD-1 immunotherapy drug (nivolumab or cetrelimab). The goal is to find out if the scan can predict whether the immunotherapy will work for you.
AmsterdamAges 18 years+ - NCT06638034RecruitingEarly Phase 1
New imaging and radiation therapy for metastatic tumors
This trial tests a new type of imaging scan and treatment for cancers that have spread. You would first have two special scans, then you may receive a targeted radiation therapy (177Lu-FAPI-RGD) to see if it can help shrink tumors.
Beijing, Beijing MunicipalityAges 18–90 - NCT06155318Recruiting
PET scan for neuroendocrine tumors
This trial tests a special PET scan to better evaluate gastroenteropancreatic neuroendocrine tumors (GEP-NETs). It may help your doctor see where the tumors are in your body.
MilanAges 18 years+ - NCT06970275Recruiting
PET-CT imaging study for cancer surgery patients
This trial uses a special PET-CT scanner to take high-resolution images of cancer tumors that have been surgically removed. The goal is to see how well these images match the results from standard lab tests, such as pathology, and to track long-term outcomes.
GhentAges 18 years+ - NCT07052214RecruitingPhase 3
PSMA PET plus MRI to find prostate cancer
This trial tests if combining a PSMA PET scan with an MRI can better detect clinically significant prostate cancer than MRI alone. It may help men who have not had a prostate biopsy before and have certain risk factors.
Los Angeles, CaliforniaAges 18 years+ - NCT06096870RecruitingPhase 2
Enzalutamide with a new drug for prostate cancer that is active on PET scan
This trial tests a combination of enzalutamide (a hormone blocker) and an investigational antibody-drug (PDS01ADC) in men whose prostate cancer has come back after initial treatment, but has not yet spread extensively. It does not involve standard hormone therapy that lowers testosterone.
Bethesda, MarylandAges 18–120 - NCT03495427RecruitingPhase 2/Phase 3
PSMA PET scan to find early prostate cancer spread
This study uses a PSMA PET scan to look for early spread of prostate cancer in men with higher-risk genetic test results (Decipher score above 0.45). It may help doctors spot metastases sooner so treatment decisions can be better targeted.
Tampa, FloridaAges 18 years+ - NCT03853915Recruiting
PET scan and HPV testing during chemoradiation for cervical cancer
This study looks at whether a PET scan (FDG-PET/CT) and blood HPV testing can help track cervical cancer responses during and after standard chemo-radiation. It may help doctors better understand who is responding and who may need different care.
Toronto, OntarioAges 18 years+ - NCT03860857RecruitingPhase 3
Study biomarkers in memory aging and brain health
This Phase 3 study looks for blood/brain “biomarkers” linked to aging, memory changes, and early brain degeneration. It may help researchers better identify who is at risk and how biology relates to thinking and memory, using brain scans and thinking tests.
Irvine, CaliforniaAges 60 years+ - NCT03888950Recruiting
Interim PET-CT scan to assess anti-PD-1 treatment in melanoma
This study checks an “interim” whole-body scan (PET-CT) partway through treatment to see how well anti-PD-1 immunotherapy (nivolumab or pembrolizumab) is working for advanced melanoma. It may help doctors better understand early treatment response and guide next steps.
Nice, CHU de NICEAges 18 years+ - NCT03998852RecruitingPhase 3
PET study of brain chemical changes in stroke apathy
This Phase 3 trial uses special brain scans (PET) to understand what brain chemical systems are involved in apathy after stroke. Your results may help researchers better understand the cause of apathy and guide future treatments.
BordeauxAges 18–75 - NCT04073797Recruiting
PET scan study of inflammation and cholesterol-lowering treatment
This study uses PET/CT and related scans to measure inflammation in artery plaque and how cholesterol-lowering treatment changes it. It may help researchers understand which treatments reduce artery inflammation for people with heart or blood-vessel disease and high LDL (“bad”) cholesterol.
CambridgeAges 18–99 - NCT04390009RecruitingEarly Phase 1
Whole-body PET scans in people with multiple sclerosis
This early study tests how whole-body PET-CT scans can be used in people with multiple sclerosis (and compares with healthy volunteers). It may help researchers understand what the scan can show in MS throughout the body.
Ladera Ranch, CaliforniaAges 25–55 - NCT04927416RecruitingPhase 2
Ga-DOTATATE PET/CT scan in metastatic thyroid cancer
This study tests whether a specific special scan (68-Gallium DOTATATE PET/CT) can help doctors better see where thyroid cancer has spread. It focuses on certain types of thyroid cancer and compares how well the scan images metastases.
Bethesda, MarylandAges 18–98
Hear when a new PET trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for pet?
- Yes. Clin2 currently lists 590 recruiting pet studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a pet trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a pet trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.